Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM0SYAN)

Drug Name
Almitrine Drug Info
Synonyms
Almitrin; Almitrina; Almitrinum; Vectarion; Almitrine bismesylate; Almitrine dimesylate; S 2620; Almitrina [INN-Spanish]; Almitrine (INN); Almitrine Bis(methanesulfonate); Almitrine [BAN:INN]; Almitrine [INN:BAN]; Almitrinum [INN-Latin]; N,N'-diallyl-6-{4-[bis(4-fluorophenyl)methyl]piperazin-1-yl}-1,3,5-triazine-2,4-diamine; 2,4-Bis(allylamino)-6-(4-(bis(p-fluorophenyl)methyl)-1-piperazinyl)-s-triazine; 2,4-bis[allylamino]-6-[4-[bis(p-fluorophenyl)methyl]-1-piperazinyl]-s-triazine; 6-(4-(Bis(4-fluorphenyl)methyl)-1-piperazinyl)-N,N'-di-2-propenyl-1,3,5-triazin-2,4-diamin; 6-[4-[bis(4-fluorophenyl)methyl]piperazin-1-yl]-2-N,4-N-bis(prop-2-enyl)-1,3,5-triazine-2,4-diamine
Therapeutic ClassAntiinflammatory Agents
Cross-matching ID
PubChem CID
33887
ChEBI ID
CHEMBL53778
CAS Number
CAS 27469-53-0
TTD Drug ID
D0D9NA

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
One carbon pool by folate 1.99 2.33e-2 15/20 (75%) SHMT2;TYMS;MTHFD2;...
Cysteine and methionine metabolism 1.94 1.55e-2 43/50 (86%) CBS;PSAT1;MTR;...
Mineral absorption 1.86 2.07e-2 48/60 (80%) MT1X;MT1F;SLC30A1;...
Cell cycle 1.79 4.84e-2 110/124 (88.71%) CDC20;SMC1A;MCM6;...
Th17 cell differentiation -1.64 4.79e-2 95/107 (88.79%) TBX21;IL4R;TGFB1;...
Viral myocarditis -1.65 4.03e-2 53/60 (88.33%) HLA-B;HLA-DPB1;CASP3;...
Oxidative phosphorylation -1.66 3.99e-2 93/133 (69.92%) ATP5PD;ATP5MC1;COX4I1;...
Metabolism of xenobiotics by cytochrome P450 -1.66 3.88e-2 49/77 (63.64%) CBR1;GSTM5;CYP1A1;...
Huntington disease -1.67 4.01e-2 233/306 (76.14%) HDAC1;SLC25A5;NDUFV2;...
Apoptosis -1.67 3.77e-2 126/168 (75%) IL3RA;CTSB;TRAF2;...
Systemic lupus erythematosus -1.73 1.92e-2 45/135 (33.33%) HLA-DPB1;SNRPD3;ACTN4;...
Allograft rejection -1.74 1.96e-2 32/38 (84.21%) CD86;TNF;HLA-DQB1;...
Inflammatory bowel disease -1.74 1.78e-2 58/65 (89.23%) TBX21;IL4R;IL5;...
Asthma -1.74 1.81e-2 25/31 (80.65%) IL5;HLA-DPB1;FCER1A;...
Proteasome -1.75 1.85e-2 44/46 (95.65%) PSMA5;PSMD7;PSMD14;...
Graft-versus-host disease -1.78 1.33e-2 32/42 (76.19%) FASLG;KLRD1;HLA-B;...
Synaptic vesicle cycle -1.79 1.44e-2 63/78 (80.77%) SLC6A12;SLC17A6;CLTC;...
Mitophagy -1.80 1.46e-2 56/68 (82.35%) GABARAPL2;ATG5;ULK1;...
Autoimmune thyroid disease -1.81 1.48e-2 46/53 (86.79%) FASLG;IFNA17;IL5;...
Steroid biosynthesis -1.82 1.51e-2 19/20 (95%) DHCR7;CYP51A1;LSS;...
Tuberculosis -1.87 7.72e-3 159/180 (88.33%) TNF;TLR2;MAPK3;...
Lysosome -1.91 1.76e-3 115/128 (89.84%) LIPA;IDUA;AP1B1;...
Antigen processing and presentation -1.98 2.06e-3 60/78 (76.92%) KLRD1;PSME3;CTSB;...
Th1 and Th2 cell differentiation -2.00 2.47e-3 80/92 (86.96%) TBX21;IL4R;IL5;...
Staphylococcus aureus infection -2.05 0.00e+0 72/95 (75.79%) FGG;KRT33A;KRT33B;...
Type I diabetes mellitus -2.07 0.00e+0 38/43 (88.37%) HLA-B;HLA-DPB1;CPE;...
Leishmaniasis -2.10 0.00e+0 67/77 (87.01%) TNF;TLR2;MAPK3;...
Phagosome -2.22 0.00e+0 118/152 (77.63%) THBS4;TLR2;ITGB5;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 10uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.01uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 10uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.04uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 24H
Umbilical vein
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HUVEC-C CVCL_2959 Homo sapiens 0.01uM - 10uM 24H